ORAMED PHARMACEUTICALS INC.
ORMPNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ORMP. That does not mean none is planned.
Get an email about ORMP's next catalysts
Track ORAMED PHARMACEUTICALS (ORMP) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
ORMP Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $0.43 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
Oramed Pharmaceuticals Inc. (Hebrew: ΧΧΧ¨ΧΧ), is a publicly traded company engaged in the development of oral drug delivery systems β most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
WebsiteORMD-0801 QD
Nonalcoholic Steatohepatitis (NASH)
ORMD-0801 (qd)
Type 2 Diabetes Mellitus
ORMD-0801 Dose # 1
Diabetes Mellitus Type 2
ORMD-0801
Diabetes Type 2
ORMD-0801 Capsules
Diabetes Mellitus Type 1
ORMD-0801 Treatment A
Type 1 Diabetes
Oral Insulin
Non-Alcoholic Steatohepatitis (NASH)
ORMD-0801 (Insulin) capsule BD
Diabetes Mellitus, Type 2
ORMD 0801
Brittle Type I Diabetes Mellitus
ORMD-0801 Treatment B
Type 1 Diabetes
ORMD-0801 (tid)
Type 2 Diabetes Mellitus
ORMD-0801 Dose # 2
Diabetes Mellitus Type 2
ORMD-0801 (bid)
Type 2 Diabetes Mellitus
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ORMD-0801 QD | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
ORMD-0801 (qd) | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ORMD-0801 Dose # 1 | Phase 2 | Diabetes Mellitus Type 2 | - | - |
ORMD-0801 | Phase 2 | Diabetes Type 2 | - | - |
ORMD-0801 Capsules | Phase 2 | Diabetes Mellitus Type 1 | - | - |
ORMD-0801 Treatment A | Phase 2 | Type 1 Diabetes | - | - |
Oral Insulin | Phase 2 | Non-Alcoholic Steatohepatitis (NASH) | - | - |
ORMD-0801 (Insulin) capsule BD | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
ORMD 0801 | Phase 2 | Brittle Type I Diabetes Mellitus | - | - |
ORMD-0801 Treatment B | Phase 2 | Type 1 Diabetes | - | - |
ORMD-0801 (tid) | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ORMD-0801 Dose # 2 | Phase 2 | Diabetes Mellitus Type 2 | - | - |
ORMD-0801 (bid) | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Frequently asked questions
What is in ORAMED PHARMACEUTICALS INC.'s drug pipeline?β
CatalystAlert tracks 13 drug candidates in ORAMED PHARMACEUTICALS INC.'s (ORMP) pipeline across Phase 2. Its lead program is Oral Insulin (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ORAMED PHARMACEUTICALS INC.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for ORAMED PHARMACEUTICALS INC. (ORMP) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track ORMP biotech catalysts?β
Add ORMP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ORAMED PHARMACEUTICALS INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.